| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Thursday’s Close |
|---|---|---|---|---|---|
| GSK | GlaxoSmithKline PLC | $39.21 | $97.25B | N/A |
Bausch (BHC) Q4 Earnings Beat Estimates, Revenues Down Y/Y
http://www.zacks.com/stock/news/356274/bausch-bhc-q4-earnings-beat-estimates-revenues-down-y-y?cid=CS-ZC-FT-356274
Feb 21, 2019 - Bausch (BHC) Q4 earnings and revenues surpass estimates. However, guidance for 2019 is not impressive.
0
Merck Gets Priority Review for Keytruda in Third-Line SCLC
http://www.zacks.com/stock/news/355982/merck-gets-priority-review-for-keytruda-in-third-line-sclc?cid=CS-ZC-FT-355982
Feb 21, 2019 - Merck's (MRK) sBLA looking for approval of Keytruda monotherapy for the third-line treatment of small cell lung cancer, a difficult-to-treat cancer, gets FDA's priority review.
0
Novo Nordisk Gets FDA Nod for Haemophilia Drug Esperoct
http://www.zacks.com/stock/news/355654/novo-nordisk-gets-fda-nod-for-haemophilia-drug-esperoct?cid=CS-ZC-FT-355654
Feb 20, 2019 - Novo Nordisk (NVO) clinches the FDA approval for its biologics license application in favor of Esperoct to treat adults and children suffering haemophilia A.
0
Bayer Obtains Full Rights to Vitrakvi From Lilly's Loxo
http://www.zacks.com/stock/news/355437/bayer-obtains-full-rights-to-vitrakvi-from-lillys-loxo?cid=CS-ZC-FT-355437
Feb 19, 2019 - Bayer (BAYRY) obtains full exclusive licensing rights for the global development and commercialization of Vitrakvi (larotrectinib) and BAY 2731954 (LOXO-195) from Loxo.
0
New Strong Buy Stocks for February 19th
http://www.zacks.com/commentary/213873/new-strong-buy-stocks-for-february-19th?cid=CS-ZC-FT-213873
Feb 19, 2019 - New Strong Buy Stocks for February 19th
0
Top Ranked Growth Stocks to Buy for February 15th
http://www.zacks.com/commentary/213938/top-ranked-growth-stocks-to-buy-for-february-15th?cid=CS-ZC-FT-213938
Feb 15, 2019 - Top Ranked Growth Stocks to Buy for February 15th
0
Johnson & Johnson (JNJ) to Acquire Auris Health for $3.4B
http://www.zacks.com/stock/news/354868/johnson-johnson-jnj-to-acquire-auris-health-for-%2434b?cid=CS-ZC-FT-354868
Feb 14, 2019 - Johnson & Johnson (JNJ) entered into a definitive agreement to acquire Auris Health, Inc., a developer of robotic technologies focused on lung cancer, for approximately $3.4 billion in cash.
0
Top Ranked Income Stocks to Buy for February 14th
http://www.zacks.com/commentary/213612/top-ranked-income-stocks-to-buy-for-february-14th?cid=CS-ZC-FT-213612
Feb 14, 2019 - Top Ranked Income Stocks to Buy for February 14th
0
New Strong Buy Stocks for February 14th
http://www.zacks.com/commentary/213348/new-strong-buy-stocks-for-february-14th?cid=CS-ZC-FT-213348
Feb 14, 2019 - New Strong Buy Stocks for February 14th
0
AstraZeneca's (AZN) Q4 Earnings Beat, New Drugs Drive Sales
http://www.zacks.com/stock/news/354603/astrazenecas-azn-q4-earnings-beat-new-drugs-drive-sales?cid=CS-ZC-FT-354603
Feb 14, 2019 - AstraZeneca (AZN) beats earnings and sales estimates in the fourth quarter and provides encouraging outlook for 2019. Shares up.
0